| Identification | Back Directory | [Name]
7-Deaza-2'-C-ethynyladenosine | [CAS]
1044589-82-3 | [Synonyms]
NITD008
7-Deaza-2'-C-ethynyladenosine
7-Deaza-2'-C-acetylene-adenosine
7-(2-C-Ethynyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-ethynyl-β-D-ribofuranosyl)-
(2R,3R,4R,5R)-2-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-ethynyl-5-(hydroxymethyl)tetrahydrofuran-3,4-diol | [Molecular Formula]
C13H14N4O4 | [MDL Number]
MFCD27952796 | [MOL File]
1044589-82-3.mol | [Molecular Weight]
290.27 |
| Chemical Properties | Back Directory | [Boiling point ]
631.8±55.0 °C(Predicted) | [density ]
1?+-.0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
10.48±0.70(Predicted) | [color ]
White to gray | [InChI]
InChI=1/C13H14N4O4/c1-2-13(20)9(19)8(5-18)21-12(13)17-4-3-7-10(14)15-6-16-11(7)17/h1,3-4,6,8-9,12,18-20H,5H2,(H2,14,15,16)/t8-,9-,12-,13-/s3 | [InChIKey]
NKRAIOQPSBRMOV-YFEBQZRFNA-N | [SMILES]
C([C@]1([C@@H]([C@@H](CO)O[C@H]1N1C=CC2=C(N=CN=C12)N)O)O)#C |&1:1,2,3,7,r| |
| Hazard Information | Back Directory | [Uses]
NITD008 is an adenosine nucleoside analogue that inhibits proliferation of EV71, which is one of the major causative agents of Hand-Foot-Mouth Disease. | [Biological Activity]
NITD008 is a selective inhibitor of flaviviruses including dengue virus (EC50 = 0.64 μM)hepatitis C virus and Zika virusand has also been shown to inhibit tick-borne flaviviruses in vitro. NITD008 has been reported to inhibit RNA-dependent RNA polymerase (RdRp)an essential protein of RNA viruses. | [in vivo]
NITD008 is orally bioavailable and has good pharmacokinetic properties. NITD008 exhibits the best pharmacokinetic parameters when formulated using 6 N of HCl (1.5 equimolar amount), 1 N of NaOH (pH adjusted to 3.5), and 100 mM citrate buffer (pH 3.5). Following i.v. injection, NITD008 has a high volume of distribution (3.71 L/kg) and a low systemic clearance (31.11 mL/min per kg), resulting in a long elimination half-life (t1/2=4.99 h). After p.o. dosing, NITD008 is rapidly absorbed (time of peak plasma concentration=0.5 h), with a maximal plasma concentration of 3 μM and bioavailability of 48%. Treatment of the mice immediately after viral infection with 1 mg/kg of NITD008 does not reduce mortality, but treatment with 3 mg/kg partially protects and treatment with ≥10 mg/kg completely protects the infected mice from death. NITD008 can suppress peak viremia, decrease cytokine elevation, and prevent death[1]. | [storage]
Store at -20°C |
|
|